Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease

BackgroundDepression in patients with coronary artery disease (CAD) is associated with increased cardiovascular morbidity. Given the proinflammatory actions of phospholipids, aberrant phospholipid metabolism may be an etiological mechanism linking CAD and depression. Our primary objective was to ide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Parco Chan, Ivonne Suridjan, Dana Mohammad, Nathan Herrmann, Graham Mazereeuw, Lyn M. Hillyer, David W. L. Ma, Paul I. Oh, Krista L. Lanctôt
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2018
Materias:	cardiac rehabilitation coronary artery disease depression inflammation lipidomics lipids Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/b1a0de9f4aac4838aaf9df700ce017b3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1a0de9f4aac4838aaf9df700ce017b3
record_format	dspace
spelling	oai:doaj.org-article:b1a0de9f4aac4838aaf9df700ce017b32021-11-12T17:01:53ZNovel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease10.1161/JAHA.117.0082782047-9980https://doaj.org/article/b1a0de9f4aac4838aaf9df700ce017b32018-05-01T00:00:00Zhttps://www.ahajournals.org/doi/10.1161/JAHA.117.008278https://doaj.org/toc/2047-9980BackgroundDepression in patients with coronary artery disease (CAD) is associated with increased cardiovascular morbidity. Given the proinflammatory actions of phospholipids, aberrant phospholipid metabolism may be an etiological mechanism linking CAD and depression. Our primary objective was to identify a phospholipid biomarker panel that characterizes CAD patients with significant depressive symptoms from those without. Methods and ResultsWe performed a targeted lipidomic analysis on CAD patients with significant depressive symptoms (n=37, Center for Epidemiologic Studies Depression score ≥16) and those without (n=49). Phospholipid species were selected using partial least‐square discriminant analysis, and the ability of the resulting model to discriminate between groups was evaluated using receiver operator characteristic curves. Biosignature scores were calculated from this model, and analyses of covariance were performed to compare intergroup differences in biosignature scores, with adjustment for clinical differences between patients. Those with significant depressive symptoms had lower cardiopulmonary fitness, more prevalent history of depression, and a greater number of vascular risk factors. A model of 10 phospholipid species had an area under the curve value of 0.84 (95% confidence interval 0.72‐0.95), sensitivity of 0.73, and specificity of 0.71. This model passed permutation testing (n=1000, P<0.001). Biosignature scores were higher in those with significant depressive symptoms after adjustment for potential confounders (F[1.86]=14.39, P<0.0005). ConclusionsThe present findings support the role of proinflammatory phospholipid species in the presence of depression in CAD patients from the CAROTID trial (Coronary Artery Disease Randomized Omega‐3 Trial in Depression). Future investigations should aim to replicate findings in larger data sets and clarify possible pathophysiological mechanisms. Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT00981383.Parco ChanIvonne SuridjanDana MohammadNathan HerrmannGraham MazereeuwLyn M. HillyerDavid W. L. MaPaul I. OhKrista L. LanctôtWileyarticlecardiac rehabilitationcoronary artery diseasedepressioninflammationlipidomicslipidsDiseases of the circulatory (Cardiovascular) systemRC666-701ENJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 10 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiac rehabilitation coronary artery disease depression inflammation lipidomics lipids Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	cardiac rehabilitation coronary artery disease depression inflammation lipidomics lipids Diseases of the circulatory (Cardiovascular) system RC666-701 Parco Chan Ivonne Suridjan Dana Mohammad Nathan Herrmann Graham Mazereeuw Lyn M. Hillyer David W. L. Ma Paul I. Oh Krista L. Lanctôt Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
description	BackgroundDepression in patients with coronary artery disease (CAD) is associated with increased cardiovascular morbidity. Given the proinflammatory actions of phospholipids, aberrant phospholipid metabolism may be an etiological mechanism linking CAD and depression. Our primary objective was to identify a phospholipid biomarker panel that characterizes CAD patients with significant depressive symptoms from those without. Methods and ResultsWe performed a targeted lipidomic analysis on CAD patients with significant depressive symptoms (n=37, Center for Epidemiologic Studies Depression score ≥16) and those without (n=49). Phospholipid species were selected using partial least‐square discriminant analysis, and the ability of the resulting model to discriminate between groups was evaluated using receiver operator characteristic curves. Biosignature scores were calculated from this model, and analyses of covariance were performed to compare intergroup differences in biosignature scores, with adjustment for clinical differences between patients. Those with significant depressive symptoms had lower cardiopulmonary fitness, more prevalent history of depression, and a greater number of vascular risk factors. A model of 10 phospholipid species had an area under the curve value of 0.84 (95% confidence interval 0.72‐0.95), sensitivity of 0.73, and specificity of 0.71. This model passed permutation testing (n=1000, P<0.001). Biosignature scores were higher in those with significant depressive symptoms after adjustment for potential confounders (F[1.86]=14.39, P<0.0005). ConclusionsThe present findings support the role of proinflammatory phospholipid species in the presence of depression in CAD patients from the CAROTID trial (Coronary Artery Disease Randomized Omega‐3 Trial in Depression). Future investigations should aim to replicate findings in larger data sets and clarify possible pathophysiological mechanisms. Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT00981383.
format	article
author	Parco Chan Ivonne Suridjan Dana Mohammad Nathan Herrmann Graham Mazereeuw Lyn M. Hillyer David W. L. Ma Paul I. Oh Krista L. Lanctôt
author_facet	Parco Chan Ivonne Suridjan Dana Mohammad Nathan Herrmann Graham Mazereeuw Lyn M. Hillyer David W. L. Ma Paul I. Oh Krista L. Lanctôt
author_sort	Parco Chan
title	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
title_short	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
title_full	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
title_fullStr	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
title_full_unstemmed	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease
title_sort	novel phospholipid signature of depressive symptoms in patients with coronary artery disease
publisher	Wiley
publishDate	2018
url	https://doaj.org/article/b1a0de9f4aac4838aaf9df700ce017b3
work_keys_str_mv	AT parcochan novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT ivonnesuridjan novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT danamohammad novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT nathanherrmann novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT grahammazereeuw novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT lynmhillyer novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT davidwlma novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT paulioh novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease AT kristallanctot novelphospholipidsignatureofdepressivesymptomsinpatientswithcoronaryarterydisease
_version_	1718430390036725760

Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease

Ejemplares similares